메뉴 건너뛰기




Volumn 23, Issue 4, 2011, Pages 339-345

How to measure disease activity in axial spondyloarthritis?

Author keywords

ankylosing spondylitis; disease activity; outcomes research; spondyloarthritis; validity

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; TUMOR NECROSIS FACTOR INHIBITOR;

EID: 79958844057     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283470f23     Document Type: Article
Times cited : (57)

References (22)
  • 1
    • 0028575453 scopus 로고
    • A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index
    • Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21:2286-2291.
    • (1994) J Rheumatol , vol.21 , pp. 2286-2291
    • Garrett, S.1    Jenkinson, T.2    Kennedy, L.G.3
  • 4
    • 70449721120 scopus 로고    scopus 로고
    • Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations
    • Song IH, Rudwaleit M, Listing J, et al. Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations. Ann Rheum Dis 2009; 68: 1701-1707.
    • (2009) Ann Rheum Dis , vol.68 , pp. 1701-1707
    • Song, I.H.1    Rudwaleit, M.2    Listing, J.3
  • 6
    • 58349090431 scopus 로고    scopus 로고
    • Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis
    • Lukas C, Landewe R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68:18-24.
    • (2009) Ann Rheum Dis , vol.68 , pp. 18-24
    • Lukas, C.1    Landewe, R.2    Sieper, J.3
  • 8
    • 72249090182 scopus 로고    scopus 로고
    • ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis
    • Van der Heijde D, Lie E, Kvien TK, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68:1811-1818.
    • (2009) Ann Rheum Dis , vol.68 , pp. 1811-1818
    • Van Der Heijde, D.1    Lie, E.2    Kvien, T.K.3
  • 9
    • 23644434603 scopus 로고    scopus 로고
    • The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: A six-month, longitudinal, observational, multicenter study
    • DOI 10.1002/art.21209
    • Heiberg MS, Nordvag BY, Mikkelsen K, et al. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study. Arthritis Rheum 2005; 52: 2506-2512. (Pubitemid 41117438)
    • (2005) Arthritis and Rheumatism , vol.52 , Issue.8 , pp. 2506-2512
    • Heiberg, M.S.1    Nordvag, B.-Y.2    Mikkelsen, K.3    Rodevand, E.4    Kaufmann, C.5    Mowinckel, P.6    Kvien, T.K.7
  • 10
    • 79958857590 scopus 로고    scopus 로고
    • Endorsement of the definitions of disease activity states and improvement scores for the Ankylosing Spondylitis Disease Activity Score (ASDAS): Results from the Outcome Measures in Rheumatology (OMERACT) 10 conference
    • in press
    • Machado P, Landewe R, van der Heijde D. Endorsement of the definitions of disease activity states and improvement scores for the Ankylosing Spondylitis Disease Activity Score (ASDAS): results from the Outcome Measures in Rheumatology (OMERACT) 10 conference. J Rheumatol (in press).
    • J Rheumatol
    • MacHado, P.1    Landewe, R.2    Van Der Heijde, D.3
  • 11
    • 78650657046 scopus 로고    scopus 로고
    • Ankylosing Spondylitis Disease Activity Score (ASDAS): Defining cut-off values for disease activity states and improvement scores
    • Machado P, Landewe R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011; 70:47-53.
    • (2011) Ann Rheum Dis , vol.70 , pp. 47-53
    • MacHado, P.1    Landewe, R.2    Lie, E.3
  • 12
    • 77953710657 scopus 로고    scopus 로고
    • Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors
    • Pedersen SJ, Sorensen IJ, Hermann KG, et al. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 2010; 69:1065-1071.
    • (2010) Ann Rheum Dis , vol.69 , pp. 1065-1071
    • Pedersen, S.J.1    Sorensen, I.J.2    Hermann, K.G.3
  • 13
    • 77955386556 scopus 로고    scopus 로고
    • Discrimination ability of ASDAS estimating disease activity status in patients with ankylosing spondylitis
    • Nas K, Yildirim K, Cevik R, et al. Discrimination ability of ASDAS estimating disease activity status in patients with ankylosing spondylitis. Int J Rheum Dis 2010; 13:240-245.
    • (2010) Int J Rheum Dis , vol.13 , pp. 240-245
    • Nas, K.1    Yildirim, K.2    Cevik, R.3
  • 14
    • 78650581154 scopus 로고    scopus 로고
    • Active disease requiring TNF-alpha-antagonist therapy can be well discriminated with different ASDAS sets: A prospective, follow-up of disease activity assessment in ankylosing spondylitis
    • Aydin SZ, Can M, Atagunduz P, et al. Active disease requiring TNF-alpha-antagonist therapy can be well discriminated with different ASDAS sets: a prospective, follow-up of disease activity assessment in ankylosing spondylitis. Clin Exp Rheumatol 2010; 28:752-755.
    • (2010) Clin Exp Rheumatol , vol.28 , pp. 752-755
    • Aydin, S.Z.1    Can, M.2    Atagunduz, P.3
  • 15
    • 78649749326 scopus 로고    scopus 로고
    • Is ASDAS better than BASDAIasameasureof disease activity in axial psoriatic arthritis?
    • Eder L, Chandran V, Shen H, et al. Is ASDAS better than BASDAIasameasureof disease activity in axial psoriatic arthritis? Ann Rheum Dis 2010; 69:2160-2164.
    • (2010) Ann Rheum Dis , vol.69 , pp. 2160-2164
    • Eder, L.1    Chandran, V.2    Shen, H.3
  • 16
    • 79958781492 scopus 로고    scopus 로고
    • Evaluation of the newASAS instrument to assess disease activity, the ASDAS, in patients with ankylosing spondylitis treated with TNF blockersover 8 years
    • abstract 526
    • Baraliakos X, Fritz C, Listing J, et al. Evaluation of the newASAS instrument to assess disease activity, the ASDAS, in patients with ankylosing spondylitis treated with TNF blockersover 8 years. In: 2010 Annual Scientific Meeting of the American College of Rheumatology (ACR); abstract 526.
    • 2010 Annual Scientific Meeting of the American College of Rheumatology (ACR)
    • Baraliakos, X.1    Fritz, C.2    Listing, J.3
  • 17
    • 79958864117 scopus 로고    scopus 로고
    • Evaluation of the New Ankylosing Spondylitis Disease Activity Score (ASDAS) to assess disease activity in patient with active non-radiographic axial spondyloarthritis treated with adalimumab and retreated after interruption of therapy and flare
    • abstract 1938
    • Haibel H, Heldmann F, Listing J, et al. Evaluation of the New Ankylosing Spondylitis Disease Activity Score (ASDAS) to assess disease activity in patient with active non-radiographic axial spondyloarthritis treated with adalimumab and retreated after interruption of therapy and flare. In: 2010 Annual Scientific Meeting of the American College of Rheumatology (ACR); abstract 1938.
    • 2010 Annual Scientific Meeting of the American College of Rheumatology (ACR)
    • Haibel, H.1    Heldmann, F.2    Listing, J.3
  • 18
    • 79958780201 scopus 로고    scopus 로고
    • Clinical improvement with etanercept versus sulfasalazine treatment in patients with Ankylosing Spondylitis: Comparative Performance of Various Efficacy Measurements (ASCEND)
    • abstract 1927
    • Van der Heijde D, Braun J, Dougados M, et al. Clinical improvement with etanercept versus sulfasalazine treatment in patients with Ankylosing Spondylitis: Comparative Performance of Various Efficacy Measurements (ASCEND). In: 2010 Annual Scientific Meeting of the American College of Rheumatology (ACR); abstract 1927.
    • 2010 Annual Scientific Meeting of the American College of Rheumatology (ACR)
    • Van Der Heijde, D.1    Braun, J.2    Dougados, M.3
  • 20
    • 77954964488 scopus 로고    scopus 로고
    • Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and nonradiographic axial spondyloarthritis
    • Poddubnyy DA, Rudwaleit M, Listing J, et al. Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and nonradiographic axial spondyloarthritis. Ann Rheum Dis 2010; 69:1338-1341.
    • (2010) Ann Rheum Dis , vol.69 , pp. 1338-1341
    • Poddubnyy, D.A.1    Rudwaleit, M.2    Listing, J.3
  • 22
    • 0031990046 scopus 로고    scopus 로고
    • The OMERACT filter for outcome measures in rheumatology
    • Boers M, Brooks P, Strand CV, et al. The OMERACT filter for outcome measures in rheumatology. J Rheumatol 1998; 25:198-199.
    • (1998) J Rheumatol , vol.25 , pp. 198-199
    • Boers, M.1    Brooks, P.2    Strand, C.V.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.